Athenex Inc logo

ATNX - Athenex Inc Share Price

$12.38 0.9  7.7%

Last Trade - 22/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £844.4m
Enterprise Value £758.1m
Revenue £114.7m
Position in Universe 2577th / 6630
Bullish
Bearish
Unlock ATNX Revenue
Momentum
Relative Strength (%)
1m +2.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1.21 13.9 20.6 38.0 89.1 101.2 139.6 160.9 +142.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AthenexInc revenues increased 83% to $122.6M. Net loss decreased5% to $96.7M. Revenues reflect Oncology Innovation Platformsegment increase from $422K to $38.8M, Commercial Platformsegment increase of 92% to $73.5M, China segment increasefrom $1.8M to $39.6M, United Kingdom segment increase from$1M to $19.3M. Lower net loss reflects Research anddevelopment expenses decrease of 9% to $54.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ATNX Revenue Unlock ATNX Revenue

Net Income

ATNX Net Income Unlock ATNX Revenue

Normalised EPS

ATNX Normalised EPS Unlock ATNX Revenue

PE Ratio Range

ATNX PE Ratio Range Unlock ATNX Revenue

Dividend Yield Range

ATNX Dividend Yield Range Unlock ATNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATNX EPS Forecasts Unlock ATNX Revenue
Profile Summary

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated November 4, 2003
Public Since June 14, 2017
No. of Shareholders: 115
No. of Employees: 574
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 93,339,242
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ATNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ATNX
Upcoming Events for ATNX
Frequently Asked Questions for Athenex Inc
What is the Athenex Inc share price?

As of 22/01/21, shares in Athenex Inc are trading at $12.38, giving the company a market capitalisation of £844.4m. This share price information is delayed by 15 minutes.

How has the Athenex Inc share price performed this year?

Shares in Athenex Inc are currently trading at $12.38 and the price has moved by -17.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Athenex Inc price has moved by -29.46% over the past year.

What are the analyst and broker recommendations for Athenex Inc?

Of the analysts with advisory recommendations for Athenex Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Athenex Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Athenex Inc next release its financial results?

Athenex Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Athenex Inc dividend yield?

Athenex Inc does not currently pay a dividend.

Does Athenex Inc pay a dividend?

Athenex Inc does not currently pay a dividend.

When does Athenex Inc next pay dividends?

Athenex Inc does not currently pay a dividend.

How do I buy Athenex Inc shares?

To buy shares in Athenex Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Athenex Inc?

Shares in Athenex Inc are currently trading at $12.38, giving the company a market capitalisation of £844.4m.

Where are Athenex Inc shares listed? Where are Athenex Inc shares listed?

Here are the trading details for Athenex Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ATNX
What kind of share is Athenex Inc?

Based on an overall assessment of its quality, value and momentum, Athenex Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Athenex Inc share price forecast 2021?

Shares in Athenex Inc are currently priced at $12.38. At that level they are trading at 0.121% discount to the analyst consensus target price of 0.00.

Analysts covering Athenex Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.588 for the next financial year.

How can I tell whether the Athenex Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athenex Inc. Over the past six months, the relative strength of its shares against the market has been -8.3%. At the current price of $12.38, shares in Athenex Inc are trading at 5.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Athenex Inc PE Ratio?

We were not able to find PE ratio data for Athenex Inc.

Who are the key directors of Athenex Inc?

Athenex Inc's management team is headed by:

Johnson Lau - CHM
Jeffrey Yordon - COO
Rudolf Kwan - OTH
Simon Pedder - OTH
William Zuo - CEX
Kim Campbell - LED
Manson Fok - DRC
Stephanie Davis - IND
Jordan Kanfer - IND
Randoll Sze - CFO
Daniel Lang - SDR
Robert Spiegel - DRC
Who are the major shareholders of Athenex Inc?

Here are the top five shareholders of Athenex Inc based on the size of their shareholding:

Perceptive Advisors LLC Private Equity
Percentage owned: 14.5% (13.5m shares)
Ma (Huateng) Individual Investor
Percentage owned: 6.65% (6.21m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.9% (4.57m shares)
Beansprouts Ltd. Corporation
Percentage owned: 4.53% (4.23m shares)
Lau Johnson Yiu Nam Individual Investor
Percentage owned: 4.41% (4.12m shares)
Similar to ATNX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.